Garland J. Scott — SEC Form 4 filings
SEC reporting owner CIK 1533228. 13 Form 4 filings on record with FilingPulse; latest filed 2026-06-23.
Transaction summary — filings shown
Covers all 13 filings on record, filed 2024-05-28 to 2026-06-23. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 30.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Day One Biopharmaceuticals, Inc. (DAWN) | Director | 4 | — | — | 17 |
| LB PHARMACEUTICALS INC (LBRX) | Director | 2 | — | — | 6 |
| Olema Pharmaceuticals, Inc. (OLMA) | Director | 3 | — | — | 3 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | Director | 2 | — | — | 2 |
| Enliven Therapeutics, Inc. (ELVN) | Director | 2 | — | — | 2 |
Form 4 filings — Garland J. Scott
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-23 | 4 | Olema Pharmaceuticals, Inc. (OLMA) | Grant/award (A): 29,500 (derivative) @ $0 | EDGAR |
| 2026-06-05 | 4 | LB PHARMACEUTICALS INC (LBRX) | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2026-04-23 | 4 | Day One Biopharmaceuticals, Inc. (DAWN) | Disposition to issuer (D): 48,072 (derivative) · Disposition to issuer (D): 28,700 (derivative) · Disposition to issuer (D): 37,500 (derivative) · Disposition to issuer (D): 32,335 (derivative) · Disposition to issuer (D): 22,500 (derivative) · Disposition to issuer (D): 15,000 (derivative) | EDGAR |
| 2026-02-17 | 4 | Enliven Therapeutics, Inc. (ELVN) | Grant/award (A): 1,427 (derivative) @ $0 | EDGAR |
| 2026-01-21 | 4 | ALX ONCOLOGY HOLDINGS INC (ALXO) | Grant/award (A): 40,400 (derivative) @ $0 | EDGAR |
| 2026-01-09 | 4 | Enliven Therapeutics, Inc. (ELVN) | Grant/award (A): 59,372 (derivative) @ $0 | EDGAR |
| 2025-11-07 | 4 | Day One Biopharmaceuticals, Inc. (DAWN) | Disposition to issuer (D): 48,072 (derivative) @ $0 · Grant/award (A): 48,072 (derivative) @ $0 · Disposition to issuer (D): 28,700 (derivative) @ $0 · Grant/award (A): 28,700 (derivative) @ $0 · Disposition to issuer (D): 37,500 (derivative) @ $0 · Grant/award (A): 37,500 (derivative) @ $0 · +2 more | EDGAR |
| 2025-09-12 | 4 | LB PHARMACEUTICALS INC (LBRX) | Disposition to issuer (D): 17,929 (derivative) · Grant/award (A): 17,929 (derivative) · Disposition to issuer (D): 3,585 (derivative) · Grant/award (A): 3,585 (derivative) · Grant/award (A): 22,449 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | Olema Pharmaceuticals, Inc. (OLMA) | Grant/award (A): 24,150 (derivative) @ $0 | EDGAR |
| 2025-06-04 | 4 | Day One Biopharmaceuticals, Inc. (DAWN) | Grant/award (A): 22,500 (derivative) @ $0 · Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2024-06-18 | 4 | Olema Pharmaceuticals, Inc. (OLMA) | Grant/award (A): 23,000 (derivative) @ $0 | EDGAR |
| 2024-06-14 | 4 | ALX ONCOLOGY HOLDINGS INC (ALXO) | Grant/award (A): 20,200 (derivative) @ $0 | EDGAR |
| 2024-05-28 | 4 | Day One Biopharmaceuticals, Inc. (DAWN) | Grant/award (A): 32,335 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1533228 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →